EC Dental Science

Commentary Volume 22 Issue 8 - 2023

Spittle and Aqueduct-Salivary Duct Carcinoma

Anubha Bajaj*

Department of Histopathology, Panjab University, A.B. Diagnostics, India

*Corresponding Author: Anubha Bajaj, Department of Histopathology, Panjab University, A.B. Diagnostics, India.
Received: July 01, 2023; Published: July 24, 2023



Salivary duct carcinoma represents as a malignant, high grade salivary gland neoplasm which morphologically simulates invasive ductal carcinoma of breast and manifests an in situ and invasive component. Salivary duct carcinoma was initially scripted by Kleinsasser in 1968.

As a malignant, high grade neoplasm of salivary glands delineating histological features akin to invasive ductal carcinoma of breast, tumefaction is predominantly (> 90%) immune reactive to luminal androgen receptors (AR). Besides, foci of in situ duct carcinoma frequently display comedo necrosis.

Additionally designated as high grade ductal carcinoma, salivary duct carcinoma represents ~10% of malignant salivary gland neoplasms. Tumefaction is accompanied by inferior prognostic outcomes.

Salivary duct carcinoma commonly incriminates subjects within 6th decade to 7th decade with mean age of disease emergence at 67.4 years. Nevertheless, neoplasm may arise within a comprehensive age range of 33 years to 92 years. A male predilection is encountered with male to female proportion of ~2.4:1 [1,2].

Salivary duct carcinoma preponderantly incriminates parotid gland. Besides, submandibular gland or minor salivary glands may be implicated.

Anubha Bajaj. "Spittle and Aqueduct-Salivary Duct Carcinoma". EC Dental Science 22.8 (2023): 01-04.